United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Precision BioSciences $75m stock and warrant offering sparks debate over biotech funding momentum Precision BioSciences completes a $75 million stock and warrant offering to fund its ARCUS gene-editing pipeline — find out how this move reflects broader biotech funding trends. bySoujanya RaviNovember 11, 2025